Jeff Yass’s Citius Pharmaceuticals CTXR Stock Holding History

Jeff Yass’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,100	Closed	-$53.1K	–	13302
2025 Q4	$53.1K	Buy	68,100 +45,300	+199%	+$56.6K	﹤0.01%	11732
2025 Q3	$28.3K	Buy	22,800 +9,500	+71%	+$13.2K	﹤0.01%	11989
2025 Q2	$21.1K	Buy	+13,300	New	+$12.2K	﹤0.01%	12320
2025 Q1	–	Sell	-53,800	Closed	-$215K	–	12611
2024 Q4	$215K	Buy	+53,800	New	+$362K	﹤0.01%	10570
2023 Q3	–	Sell	-1,652	Closed	-$49.6K	–	12137
2023 Q2	$49.6K	Sell	1,652 -4,272	-72%	-$141K	﹤0.01%	11344
2023 Q1	$173K	Sell	5,924 -1,012	-15%	-$29.2K	﹤0.01%	10770
2022 Q4	$137K	Buy	6,936 +880	+15%	+$24K	﹤0.01%	10626
2022 Q3	$183K	Buy	6,056 +472	+8%	+$13K	﹤0.01%	10966
2022 Q2	$128K	Sell	5,584 -2,072	-27%	-$56.8K	﹤0.01%	11217
2022 Q1	$343K	Sell	7,656 -7,708	-50%	-$304K	﹤0.01%	9933
2021 Q4	$592K	Sell	15,364 -6,820	-31%	-$309K	﹤0.01%	8726
2021 Q3	$1.13M	Buy	22,184 +18,996	+596%	+$953K	﹤0.01%	7250
2021 Q2	$277K	Buy	+3,188	New	+$192K	﹤0.01%	10944

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Jeff Yass's CTXR Position: Q2 2026 in Review

Jeff Yass reduced its Citius Pharmaceuticals (CTXR) stake by 68% in Q2 2026, selling an estimated $17K and leaving 11,795 shares worth $7.13K. The position accounts for ﹤0.01% of the portfolio, ranked #13168.

Jeff Yass first reported a position in CTXR in Q4 2019 and has held it in 21 quarters since. The position peaked at $721K in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Jeff Yass held 11,795 shares of Citius Pharmaceuticals worth $7.13K as of Q2 2026.
Jeff Yass sold 25,043 Citius Pharmaceuticals shares in Q2 2026, an estimated $17K.
Citius Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13168 holding.
Jeff Yass first reported a position in Citius Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
Jeff Yass's Citius Pharmaceuticals position peaked at $721K in Q2 2021.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.